Key Takeaways
- • Jana Partners is demanding Cooper Companies replace CEO Albert White (in position since 2018) and appoint a new board chair, escalating its activist campaign with a formal letter to the company on Thursday.
- • The hedge fund is pressing Cooper to explore strategic alternatives including a potential sale or combination of its CooperVision contact-lens business with rival Bausch + Lomb, and to divest CooperSurgical's fertility and medical-device operations.
- • Cooper's stock has declined approximately 28% since Jana first disclosed its investment roughly one year ago, with shares down 16% over the past year, giving the company a current market capitalization of approximately $10 billion.
- • Jana cites prolonged underperformance driven by inventory management failures and poor capital allocation decisions, arguing that leadership and board-level changes are necessary to address operational and strategic deficiencies.
- • This represents a significant escalation from Jana's previous engagement, which had focused on encouraging Cooper to explore strategic options rather than demanding executive and board replacement.
Summary
Jana Partners has escalated its activist campaign at medical-device manufacturer Cooper Companies with a Thursday letter demanding the replacement of Chief Executive Albert White and Board Chair, and calling for the company to pursue strategic alternatives for its core business divisions. The activist hedge fund, which built its stake approximately one year ago, is now moving beyond advisory suggestions to direct calls for executive and board overhaul, citing a prolonged period of underperformance at the company.
The hedge fund's specific strategic demands include engaging potential buyers for CooperVision, Cooper's contact-lens manufacturing and vision-care business, as well as exploring the sale of CooperSurgical, which houses fertility treatments and other medical-device operations. Jana has previously suggested a potential combination of CooperVision with competitor Bausch + Lomb. White has led Cooper as CEO since 2018, overseeing the company through a period that Jana characterizes as marked by significant operational missteps.
Jana's critique centers on two core management failures: inadequate inventory management and poor capital allocation decisions. The hedge fund argues these operational shortcomings require fresh leadership to address structural and strategic issues within the organization. Cooper operates two principal business segments: CooperVision, one of the world's largest soft contact-lens manufacturers, and CooperSurgical, focused on women's health and fertility products and services.
The stock market has reflected investor concern about Cooper's performance. Since Jana's initial investment disclosure approximately one year ago, Cooper's share price has declined roughly 28%. Over the past 12 months, the stock has fallen approximately 16%, bringing the company's current market capitalization to approximately $10 billion. This performance trajectory has provided Jana with both leverage and justification for its activist intervention, positioning the hedge fund as advocating for value recovery among shareholders concerned about management execution and strategic direction.
The hedge fund's specific strategic demands include engaging potential buyers for CooperVision, Cooper's contact-lens manufacturing and vision-care business, as well as exploring the sale of CooperSurgical, which houses fertility treatments and other medical-device operations. Jana has previously suggested a potential combination of CooperVision with competitor Bausch + Lomb. White has led Cooper as CEO since 2018, overseeing the company through a period that Jana characterizes as marked by significant operational missteps.
Jana's critique centers on two core management failures: inadequate inventory management and poor capital allocation decisions. The hedge fund argues these operational shortcomings require fresh leadership to address structural and strategic issues within the organization. Cooper operates two principal business segments: CooperVision, one of the world's largest soft contact-lens manufacturers, and CooperSurgical, focused on women's health and fertility products and services.
The stock market has reflected investor concern about Cooper's performance. Since Jana's initial investment disclosure approximately one year ago, Cooper's share price has declined roughly 28%. Over the past 12 months, the stock has fallen approximately 16%, bringing the company's current market capitalization to approximately $10 billion. This performance trajectory has provided Jana with both leverage and justification for its activist intervention, positioning the hedge fund as advocating for value recovery among shareholders concerned about management execution and strategic direction.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.